Roji Menon, MD
Internal Medicine · Kensington, MDNPI 1639269046
Payments from drug & device makers
Across 124 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$466
- Novo Nordisk$341
- Lilly USA, LLC$328
- Boehringer Ingelheim$227
- GSK$196
- Dexcom, Inc.$120
- plus $975 from 22 others
What the payments were for
- Food & beverage$2,652100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $466 |
| Novo Nordisk | 14 | $341 |
| Lilly USA, LLC | 18 | $328 |
| Boehringer Ingelheim | 10 | $227 |
| GSK | 10 | $196 |
| Dexcom, Inc. | 1 | $120 |
| AbbVie | 6 | $114 |
| Pfizer | 6 | $105 |
| Sanofi Pasteur Inc. | 4 | $81 |
| Exact Sciences | 4 | $81 |
| Abbott | 4 | $79 |
| Mylan Specialty L.p. | 1 | $78 |
| Merck | 4 | $70 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Actelion Pharmaceuticals US, Inc. | 1 | $38 |
| Amgen | 2 | $37 |
| Astellas Pharma US Inc | 2 | $34 |
| Gilead | 2 | $31 |
| Seqirus USA Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$120
- AIRSUPRA$119
- RYBELSUS$116
How this compares
$2,652 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 53 | $72,639 |
| OzempicSemaglutide | 25 | $58,610 |
| RybelsusSemaglutide | 22 | $54,370 |
| FarxigaDapagliflozin Propanediol | 17 | $21,641 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $18,875 |
| MounjaroTirzepatide | 12 | $14,906 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,100 |
| Telmisartan | 227 | $8,397 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 62 | $6,779 |
| Rosuvastatin Calcium | 258 | $5,084 |
| Atorvastatin Calcium | 421 | $5,048 |
| PaxlovidNirmatrelvir/Ritonavir | 21 | $4,227 |
| SynthroidLevothyroxine Sodium | 63 | $4,194 |
| Carvedilol ErCarvedilol Phosphate | 12 | $4,113 |
| Pravastatin Sodium | 148 | $3,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $341 | $112,98047 claims |
| Boehringer IngelheimJardiance | $227 | $72,63953 claims |
| AstraZenecaFarxiga | $466 | $21,64117 claims |
| MerckJanumet | $70 | $18,87513 claims |
| Lilly USA, LLCMounjaro | $328 | $14,90612 claims |
| GSKBreo Ellipta | $196 | $9,10012 claims |
| PfizerPaxlovid | $105 | $4,22721 claims |
| AbbVieSynthroid | $114 | $4,19463 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $2,450208 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Kensington
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.